Skip to main content

Syndicate contentU.S. Food and Drug Administration

Antidepressant use increasing in the United States

A marked and broad expansion in antidepressant treatment occurred among Americans older than 6 years between 1996 and 2005, although treatment rates remain low among racial and ethnic minorities, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

Project Zero Delay accelerates drug's path to clinical trial

HOUSTON - A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D.

A crystal ball for brain cancer?

UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment. By linking high water movement in tumors to positive drug response, the UCLA team predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy.

New research reveals mothers need infant feeding information

ATLANTA (July 29, 2009) -- A systematic literature review of mothers' experiences with bottle-feeding found that while mothers recognize the benefits of breastfeeding, those who bottle-feed with infant formula do not receive adequate information and support from their healthcare providers and thus, ultimately put their baby's health at risk.

Mayo researchers find anesthesia not harmful for babies during birth process

ROCHESTER, Minn. -- Mayo Clinic researchers have found that children exposed to anesthesia during Cesarean section are not at any higher risk for learning disabilities later in life than children not delivered by C-section.

Hepatitis C infection: treatment options equally effective, likelihood of success known early on

Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.

Vyvanse CII significantly improved ADHD symptoms for children 13 hours after administration

PHILADEPHIA -- July 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in chi

NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates

Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines. The research will be under the direction of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Edible coating makes fish filets longer-lasting, healthier

CORVALLIS, Ore. -- Consumers may be able to eat longer-lasting, potentially healthier fish fillets if research at Oregon State University makes its way to the supermarket.

That's because OSU scientists have extended the shelf life of lingcod fillets and possibly made them more nutritious by dipping them into an edible, protective coating enriched with fish oil.

Data show ATryn effectively prevents serious blood clots

BOSTON, Mass., July 16, 2009 -- Data presented at the annual meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Boston show that ATryn® (Antithrombin [Recombinant]) safely prevents peri-operative and peri-partum acute deep vein thrombosis (DVT) or other venous thromboembolic events in patients with hereditary antithrombin deficiency (HD AT).

VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD

Hollywood, FL -- July 1, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).

Stanford expert lists 5 steps to boost impact of comparative effectiveness research

STANFORD, Calif. -- Comparative effectiveness research is generating buzz these days, with the recent economic stimulus package allocating $1.1 billion for these types of studies. But a researcher at the Stanford University School of Medicine is asking policymakers to take a step back and make sure that the plans for comparative effectiveness research go deep enough to make a difference.

Scientists advance safety of nanotechnology

Scientists have identified for the first time a mechanism by which nanoparticles
cause lung damage and have demonstrated that it can be combated by blocking the
process involved, taking a step toward addressing the growing concerns over the
safety of nanotechnology.

Our exposure to controversial chemical may be greater than dose considered safe

People are likely being exposed to the commonly used chemical bisphenol A (BPA) at levels much higher than the recommended safe daily dose, according to a new study in monkeys. The results will be presented Thursday at The Endocrine Society's 91st Annual Meeting in Washington, D.C.

Bisphenol A exposure increases risk of abnormal heart rhythms in female rodents

The chemical bisphenol A, commonly found in many plastic household items, has been linked to yet another health problem in animals -- an increased frequency of arrhythmias, or heartbeat irregularities, a new study found. The results, seen only in females, will be presented Saturday at The Endocrine Society's 91st Annual Meeting in Washington, D.C.



About us

Science Blog was started in August 2002. It lives, breathes and eats press releases from research organizations around the globe. Most of what you read here are press releases from the outfits named in the stories themselves. Got a news story you think belongs here? Let's talk. The other half of the equation is blog posts from readers like you. So if you have an interest in science, please register and join others like you in an ongoing, vibrant dialog about what makes the world tick. Meantime, please take a minute to read our Privacy Policy and Site Disclaimer.


Premium Drupal Themes by Adaptivethemes